Careful observation and follow-up at all times is mandatory, including clinical examination (blood pressure monitoring etc.)as well as routine laboratory screening (hematocrit, hemoglobin, thrombocyte counts etc.)during the period of EPO application to prevent augmentation of prothrombotic constellations in addition to the known hypercoagulable state in COVID-19 (Bilaloglu et al. 2020; Klok et al. 2020; Levi et al. 2020). Here, EPO is linked to COVID-19.